Physician profile
James Choi
NPI 1063907947
$7,447.49
in general payments reported to CMS, 2019-2025
35 companies · $4,141 in 2025
The $4,141 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.70 · 2020: $39.97 · 2021: $151 · 2022: $632 · 2023: $1,266 · 2024: $1,172 · 2025: $4,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,601 · Education: $2,763 · Travel and Lodging: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,601.31 |
| Education | $2,762.97 |
| Travel and Lodging | $214.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,005.35 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $1,214.57 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $629.66 | 2022-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Glaxosmithkline, LLC. | $444.34 | 2023-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Grifols USA, LLC | $257.02 | 2023-2024 | Prolastin-C Liquid, Xembify |
| Regeneron Healthcare Solutions, INC. | $232.61 | 2024-2025 | Dupixent |
| Mylan Specialty L.P. | $202.36 | 2020-2024 | Yupelri |
| Sanofi-Aventis U.S. LLC | $182.98 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $121.28 | 2022-2025 | |
| Insmed, INC. | $116.14 | 2022-2025 | Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $114.44 | 2023-2025 | |
| Genzyme Corporation | $85.72 | 2023-2025 | |
| Verona Pharma, INC. | $83.46 | 2025 | Ohtuvayre |
| Actelion Pharmaceuticals US, INC. | $79.99 | 2023 | Opsumit, Uptravi |
| Avadel Cns Pharmaceuticals, LLC | $59.84 | 2024-2025 | Lumryz |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $58.43 | 2025 | Yupelri |
| Pfizer INC. | $58.07 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $46.88 | 2021-2024 | Recarbrio, Zerbaxa, Dificid |
| Axsome Therapeutics, INC. | $46.09 | 2023-2025 | Sunosi |
| United Therapeutics Corporation | $44.92 | 2022-2023 | Tyvaso |
| Ucb, INC. | $40.55 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.26 | 2023-2025 | Gammagard, Glassia |
| E.R. Squibb & Sons, L.L.C. | $33.80 | 2021 | |
| Gilead Sciences, INC. | $29.66 | 2021 | |
| Baxter Healthcare | $28.90 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Melinta Therapeutics, LLC | $27.61 | 2021-2022 | |
| Philips North America LLC | $25.04 | 2025 | Vest Therapy Und |
| Harmony Biosciences LLC | $21.23 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.02 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $18.34 | 2019 | |
| Mallinckrodt Hospital Products INC. | $17.61 | 2025 | Acthar |
| Abbvie INC. | $17.01 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.95 | 2022 | |
| Amgen INC. | $13.73 | 2019 | |
| Sanofi Pasteur INC. | $13.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.